OncoMatch/Clinical Trials/NCT06951997
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Is NCT06951997 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including QL1706 and Chidamide for metastatic pancreatic cancer.
Treatment: QL1706 · Chidamide · Gemcitabine · Nab-paclitaxel — This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies)
Cannot have received: immune checkpoint agonist (anti-ICOS, anti-CD40, anti-CD137, anti-GITR, anti-OX40)
immune checkpoint agonists (e.g., anti-ICOS/CD40/CD137/GITR/OX40 antibodies)
Cannot have received: immune cell therapy (CAR-T)
immune cell therapy (e.g., CAR-T)
Lab requirements
Blood counts
platelet count ≥90x10^9/l, white blood cell count ≥ 3.5 × 10⁹/l, absolute neutrophil count (anc) ≥1.5x10^9/l, hemoglobin > 90g/l
Kidney function
urea/urea nitrogen (bun) and creatinine (cr) ≤ 1.5 × uln (and creatinine clearance rate (ccr) ≥ 50 ml/min)
Liver function
ast and alt ≤ 2.5 times uln, total bilirubin ≤ 1.5 uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%, qtcf interval (fridericia correction) < 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify